Dr. Michael Snyder

I have amazing people in my lab, as I mentioned before, who...

They come up with a lot of the ideas.

I view us as a team that tries to push forward on these various things.

I try to create an open environment where people aren't afraid to share ideas and push things forward.

Anyway, I realize we got away from the organ aging part.

If you want to go back to that.

On the aging, I mentioned how we're doing all these measurements and tracking people over time.

We've now been doing this for over 12 years on this 109.

Some have dropped off and say new ones have popped on.

And what we discovered by just looking at the healthy time points

is that people, you know, they do change over time, even in the healthy times, but they're all changing differently.

Meaning we look at the biochemical pathways.

Some will have their top biochemical pathway, dilated cardiomyopathy pathway changing, or sorry, that was dilated, sorry, that was hypertrophic cardiomyopathy signaling pathway shifted.

Other people, it's metabolic.

Some are immune.

We call these agotypes, aging pathways.

And I kind of like that a little bit better than organ aging because some of the things you pick up are like oxidative stress, which go across lots of organs, or the inflammatory inflammation that's kind of cross-organ as well.

So we call these agotypes, aging patterns that we see.

And it turns out everybody's different.

So some people will be the cardio, some people will be the metabolic, some are liver, some are kidney, based on the markers we see in the blood, and some are immune, and some are all the above or parts thereof.